Institute for Regenerative Medicine, Sechenov University, Moscow, Russian Federation.
Federal Research Clinical Center of Specialized Medical Care and Medical Technologies of the FMBA of Russia, Moscow, Russian Federation.
Curr Pharm Des. 2018;24(26):3132-3142. doi: 10.2174/1381612824666180913151059.
Ischemic Heart Disease (IHD) has been recognized as the main cause of mortality in the modern world. Application of cell therapy technologies for the IHD treatment has been actively studied from the beginning of 2000s. The review is dedicated to the use of mesenchymal stem cells (MSC) in the therapy of IHD. The strategies of the MSC modification in vitro for improvement of their regenerative potential are extensively discussed, including preconditioning to enhance the cell survival, boosting their paracrine effect and manipulating their cardiomyogenic differentiation. The optimization of the MSC delivery and opportunities related to the use of biomaterials as cell carriers are also discussed. The results of the most important clinical studies on the MSC-based IHD therapy are presented, including those completed and published in the literature and the ongoing clinical trials registered at clinicaltrials.gov by June 2018.
缺血性心脏病（IHD）已被确认为现代世界的主要死亡原因。自 21 世纪初以来，人们一直在积极研究细胞治疗技术在 IHD 治疗中的应用。本文专门讨论了间充质干细胞（MSC）在 IHD 治疗中的应用。广泛讨论了体外修饰 MSC 以提高其再生潜能的策略，包括预处理以增强细胞存活、增强其旁分泌作用和操纵其心肌生成分化。还讨论了 MSC 传递的优化以及使用生物材料作为细胞载体的相关机会。介绍了基于 MSC 的 IHD 治疗的最重要临床研究结果，包括已完成并发表在文献中的研究和截至 2018 年 6 月在 clinicaltrials.gov 注册的正在进行的临床试验。
